Pharmaceutical Launch Strategy: What the First 90 Days Decide

A pharmaceutical launch strategy is the commercial and marketing framework that determines how a new drug reaches prescribers, patients, and payers before and after regulatory approval. Done well, it aligns clinical positioning, market access, medical affairs, and promotional channels into a coherent plan with measurable milestones. Done poorly, it produces a product that clears every regulatory hurdle and then quietly underperforms in the market for reasons that were entirely predictable.

Most pharma launches that fail commercially do not fail because the drug was weak. They fail because the go-to-market thinking was weak. The science gets all the attention. The commercial strategy gets the remainder.

I have spent 20 years working across industries where the cost of a weak go-to-market plan is immediately visible in revenue numbers. Pharma is unusual in that the feedback loop is slower, the regulatory constraints are tighter, and the stakeholder map is more complex than almost any other vertical. But the underlying commercial logic is the same: if you cannot clearly articulate who you are targeting, why they should change their behaviour, and how you will reach them at the right moment, no amount of promotional spend will compensate.

If you want to situate pharmaceutical launch strategy within a broader commercial context, the Go-To-Market and Growth Strategy hub covers the frameworks and principles that apply across verticals, including the ones that transfer directly into life sciences commercialisation.

Why Most Pharma Launches Are Won or Lost Before Approval

There is a persistent myth in pharmaceutical commercialisation that launch is something that happens after approval. In reality, the commercial outcome is largely determined by decisions made 18 to 24 months before a product reaches the market. Payer negotiations, formulary positioning, KOL engagement, indication sequencing, and pricing architecture are all set before the promotional engine starts. By the time a sales force is deployed, the ceiling on what is achievable has already been established.

BCG’s analysis of biopharma launches consistently points to pre-launch market shaping as one of the highest-leverage activities available to a commercial team. This is not about generating awareness. It is about ensuring that the conditions for adoption exist when the product is available. Formulary access without prior authorisation barriers, clinical guidelines that reflect the product’s differentiated profile, and a prescriber base that already understands the unmet need the product addresses. These are not marketing outputs. They are commercial prerequisites.

I have seen this pattern play out in non-pharma contexts too. When I was at lastminute.com, we launched a paid search campaign for a music festival and generated six figures of revenue within roughly a day. That result looked fast, but the conditions that made it possible, the audience, the inventory, the offer, had been in place long before we switched the campaign on. The speed of the result was a function of the preparation, not the execution. Pharma launches work the same way, just on a longer timeline and with considerably higher stakes.

The Stakeholder Map Is More Complex Than Most Launch Teams Acknowledge

Pharmaceutical marketing is frequently described as HCP-focused, and for most specialty products that is broadly accurate. But the HCP is rarely the only decision-maker, and treating them as if they are produces a launch strategy with significant blind spots.

The actual decision architecture for most prescription drugs involves at least four distinct stakeholders: the prescribing physician, the patient, the payer (including pharmacy benefit managers and formulary committees), and in many cases a specialist or multidisciplinary team. Each of these stakeholders has different information needs, different objections, and different moments of influence in the treatment pathway. A launch strategy that does not map this architecture explicitly will default to optimising for the stakeholder the commercial team is most comfortable with, which is usually the prescriber, while underinvesting in the others.

Patient support programmes are a useful illustration. In specialty therapeutics, particularly in oncology and rare disease, patient identification and treatment initiation are often the rate-limiting step, not prescriber willingness. A physician may be highly motivated to prescribe a product but face a patient who cannot access it due to cost, who is not being identified through existing care pathways, or who drops off between diagnosis and treatment initiation. The promotional investment in reaching that physician is largely wasted if the downstream barriers are not addressed.

This is where digital marketing due diligence becomes genuinely useful. Before committing budget to any channel, a rigorous audit of the full patient and prescriber experience, including where it breaks down, will tell you more about where to invest than any channel benchmarking exercise will.

Positioning in a Crowded Therapeutic Area Requires More Than Differentiation Claims

Every pharmaceutical brand claims differentiation. Efficacy, tolerability, dosing convenience, mechanism of action. In competitive therapeutic areas, these claims are often marginal and the prescriber knows it. The clinical data packages for competing products frequently overlap more than the marketing materials suggest, and experienced specialists are adept at reading through promotional positioning to the underlying evidence.

Effective positioning in this environment requires something more specific than a differentiation claim. It requires a clinical story that connects the product’s mechanism to a patient population where that mechanism genuinely matters. The narrower and more precise that population definition, the more credible the positioning becomes. A product that is “better for everyone” is a product that is compelling to no one. A product that is “the right choice for patients with X characteristic who have failed Y therapy” is a product that a specialist can use.

I was reminded of this dynamic early in my agency career. I was handed the whiteboard pen mid-brainstorm for a Guinness brief when the founder had to leave for a client meeting. The instinct in that room was to reach for broad, emotionally resonant territory. What cut through was something much more specific: a precise behavioural insight about a particular drinking occasion. The specificity was what made it actionable. The same logic applies to pharmaceutical positioning. Precision beats breadth, particularly when the audience is clinically sophisticated.

This connects directly to the principles behind corporate and business unit marketing frameworks, where the tension between brand-level positioning and product-level specificity is a recurring structural challenge. Pharma companies with large portfolios face exactly this tension at launch, particularly when a new product competes in a category where an existing company product already has presence.

Channel Strategy for HCP Engagement Has Changed More Than Most Launch Plans Reflect

The pharmaceutical sales force is not dead, but its role has changed significantly. In primary care, the economics of large field forces are increasingly difficult to justify. In specialty, the access problem has intensified: specialists are harder to reach, more time-constrained, and more likely to engage with clinical information through digital channels than through rep visits. A launch plan built around field force as the primary channel, with digital as a supplementary layer, is working from a model that is at least five years out of date.

The more productive framing is to treat the field force as one node in an omnichannel engagement model, with digital channels carrying a proportionally larger share of the educational and promotional workload. This requires a different kind of content strategy, one built around the specific information needs of different prescriber segments at different points in the adoption curve, rather than a single promotional narrative broadcast across all channels.

Endemic advertising deserves particular attention in this context. Contextually targeted placements in professional medical publications and HCP platforms consistently outperform broad programmatic buys for specialty products, for the straightforward reason that the audience is already in the right mindset when they encounter the content. A cardiologist reading a clinical journal article about heart failure management is a fundamentally different prospect than the same cardiologist scrolling a general news feed. The context shapes the receptivity, and the channel economics reflect that.

Go-to-market execution has become genuinely harder across most industries, and pharma is not exempt from this. Fragmented attention, increased channel complexity, and more sophisticated audiences all push in the same direction: toward more targeted, more personalised, and more contextually relevant engagement. The launch teams that recognise this and build their channel mix accordingly will outperform those that default to historical allocation patterns.

Market Access Is a Marketing Problem, Not Just a Reimbursement Problem

Market access is frequently siloed from the commercial marketing function in pharmaceutical organisations. It sits in its own team, with its own stakeholders and its own metrics, and the handoff between market access and commercial is often poorly managed. This is a structural problem that has direct consequences for launch performance.

The reason market access is a marketing problem is that payer decision-making is shaped by the same forces that shape prescriber decision-making: the perceived value of the product relative to existing options, the quality and relevance of the evidence, and the credibility of the clinical story being told. A market access team that is operating from a different value narrative than the commercial team is creating confusion in the market, not clarity. Payers talk to physicians. KOLs advise both clinical guideline committees and payer formulary processes. The messaging needs to be coherent across these audiences, even if the specific emphasis differs.

The parallel in financial services is instructive. B2B financial services marketing faces a similar challenge: complex products, sophisticated buyers, regulatory constraints on claims, and a multi-stakeholder decision process where the person who uses the product is rarely the person who approves the purchase. The commercial discipline required to handle that environment, particularly the rigour around value articulation and stakeholder mapping, transfers directly into pharmaceutical market access.

The BCG framework for go-to-market strategy in complex regulated markets is worth reviewing in this context. The core argument, that commercial success in regulated industries requires a more deliberate and structured approach to value communication than in consumer markets, applies directly to pharmaceutical launches.

Launch Readiness Is a Diagnostic, Not a Checklist

Launch readiness reviews are a standard part of pharmaceutical commercialisation. They are also, in my experience of working with complex organisations across multiple industries, frequently more performative than diagnostic. Teams present slides. Milestones are marked green. The review concludes that the organisation is ready. And then the launch underperforms because the readiness assessment measured activity rather than capability.

A genuine launch readiness diagnostic asks harder questions. Not “have we completed the field force training?” but “can our field force articulate the product’s clinical story in a way that a specialist will find credible and relevant?” Not “is our digital infrastructure in place?” but “do we have a clear hypothesis about which digital channels will drive prescriber behaviour change, and how will we know if that hypothesis is wrong?”

The checklist for analysing company website for sales and marketing strategy is a useful model for this kind of diagnostic thinking. The principle is the same: structured evaluation against specific commercial criteria, not a box-ticking exercise against a generic template. Applied to pharmaceutical launch, this means building readiness criteria that are specific to the product, the therapeutic area, and the competitive situation, rather than applying a standard template that looks the same regardless of context.

One of the more useful questions I have found in any launch readiness context is: “What would have to be true for this launch to fail?” Most teams are better at articulating the conditions for success than the conditions for failure. The latter is a more productive diagnostic exercise, because it surfaces the assumptions that are being made implicitly and forces the team to either validate them or acknowledge the risk they represent.

The Role of Data and Measurement in Pharmaceutical Launch

Pharmaceutical companies have access to unusually rich commercial data: prescription data at the prescriber and geography level, patient claims data, specialty pharmacy data, and increasingly, real-world evidence from electronic health records. The availability of this data is not the problem. The problem is that it is frequently used to measure what happened rather than to inform what to do next.

The most commercially useful application of prescription data in the launch context is segmentation. Not all prescribers are equal, and not all of them are equally reachable or equally likely to adopt a new product. Early in a launch, identifying which prescriber segments are showing early adoption signals, and understanding what is driving that adoption, is more valuable than tracking aggregate market share. The aggregate number is a lagging indicator. The segmentation analysis is a leading one.

This connects to a broader principle I hold about analytics: the data gives you a perspective on what is happening, not a definitive account of it. I have managed hundreds of millions in ad spend across 30 industries, and the most dangerous thing I have seen teams do is treat their measurement framework as reality rather than as an approximation of it. In pharmaceutical launch, this manifests as over-reliance on call activity metrics and reach and frequency data as proxies for commercial progress. These metrics measure input, not outcome. The distinction matters.

For teams building out their measurement architecture, pay per appointment lead generation models offer an interesting reference point. The discipline of tying commercial activity directly to a downstream outcome metric, rather than to intermediate proxies, is exactly the kind of rigour that pharmaceutical launch measurement often lacks. The specific mechanic does not translate directly, but the commercial logic does.

Indication Sequencing and Life Cycle Strategy Are Launch Decisions, Not Post-Launch Ones

For products with multiple potential indications, the sequencing question is one of the most consequential strategic decisions a commercial team will make. The first approved indication shapes how the product is perceived by prescribers, payers, and patients. That perception is sticky. Repositioning a product to a different indication or patient population after launch is significantly harder than establishing the right positioning at the outset.

This means that indication sequencing should be a commercial strategy decision, not purely a regulatory or clinical one. The clinical development programme determines what is possible. The commercial team should be influencing what is prioritised, based on a clear-eyed assessment of where the product has the strongest differentiation, the most accessible market, and the most favourable competitive dynamics.

Life cycle management planning, similarly, should begin before the first indication launches. The commercial team that is thinking about label expansions, combination strategies, and formulation development as part of the initial launch plan is building a more durable commercial asset than the team that treats these as future considerations. The decisions made at launch, about pricing, positioning, and the prescriber relationships being built, will either enable or constrain the life cycle options that are available later.

The broader principles of go-to-market strategy, including how to sequence market entry, how to build durable competitive positioning, and how to align commercial and product development priorities, are covered in more depth across the Go-To-Market and Growth Strategy hub. The pharmaceutical context adds regulatory and compliance complexity, but the underlying strategic questions are consistent with what any commercially sophisticated organisation should be asking at launch.

About the Author

Keith Lacy is a marketing strategist and former agency CEO with 20+ years of experience across agency leadership, performance marketing, and commercial strategy. He writes The Marketing Juice to cut through the noise and share what works.

Frequently Asked Questions